This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NxStage Kicks Off Annual Dialysis Conference 2012 With An Event Featuring Celebrity And Former NxStage User Stephen Furst And Others On More Frequent Home Hemodialysis

Stocks in this article: NXTM

LAWRENCE, Mass. and SAN ANTONIO, Feb. 24, 2012 /PRNewswire/ -- ADC 2012 Booth B -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it is participating in several industry-focused educational presentations on more frequent home hemodialysis with the NxStage System Oneā„¢ at the Annual Dialysis Conference (ADC) 2012. NxStage will also host a special reception event, featuring celebrity kidney transplant patient and former NxStage System One user Stephen Furst and other patient advocates. The events at ADC bring together renal care leaders and NxStage patients to promote the 'mountains of clinical data' supporting the benefits of more frequent home hemodialysis with the System One.

(Logo: )

The "Power to the Patients" reception with actor and director Stephen Furst and current NxStage patient Vanessa Evans will stress the importance of educating patients on their therapy options and empowering them to participate in their own care. Furst's successful career as an actor and director includes recent work providing character voices for the animated films "Little Mermaid II" and "Buzz Lightyear of Star Command," as well as roles in the movie "Animal House" and television shows "St. Elsewhere" and "Babylon 5." Evans is a wife, mother and long-time NxStage patient involved in dialysis patient advocacy, creating awareness for the benefits of more frequent home hemodialysis. The event will take place on Sunday, February 26 from 7:00-9:00 p.m. in Salon ABC at the Marriott Riverwalk.

In addition to the reception, NxStage will be participating in several key speaking sessions focused on home hemodialysis:

  • Technical Features of Home Hemodialysis Machines and Potential Advantages of Home Hemodialysis Robert Lockridge, MD, Presiding Monday, February 27, 2:00-4:00 p.m. Room 214 DFeaturing technical discussion of the NxStage System One, given by Daniel Call, NxStage Medical


  • "Industry Speaks" session including "NxStage: What's Now and What's Next?" Edwina Brown, MD, Presiding Monday, February 27, 6:15-8:15 p.m.Ballroom C-1Featuring a presentation by Joe Turk, President, North America, NxStage Medical

"It has been an exciting year with several significant, high-profile studies continuing to prove that more frequent home hemodialysis with the NxStage System One can deliver tremendous health and survival benefits," said Jeffrey H. Burbank, Chief Executive Officer of NxStage. "We are pleased that the significant and growing clinical data in support of our life-changing therapy will again be a key focus of ADC 2012. As the market leader, we look forward to new and continued opportunities in advancing home hemodialysis and improving the lives of patients with End Stage Renal Disease."

ADC 2012 will also feature a Home Hemodialysis Fundamentals and Symposium on Saturday, February 25, with sessions on clinical, administrative and other dialysis program and patient management topics. Registered ADC attendees are encouraged to visit NxStage Medical at Booth B.

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy.   When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand.  Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2011. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.VP, Investor Relations

SOURCE NxStage Medical, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,523.41 +166.54 0.96%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs